



Diabetes Monitoring for People with Diabetes and Schizophrenia (SMD)

HEDIS measure overview

Please note that the information offered in this flyer is based on Healthcare Effectiveness Data and Information Set (HEDIS®) technical specifications. It is not meant to preclude your clinical judgment.

What is the SMD measure?

The Diabetes Monitoring for People with Diabetes and Schizophrenia (SMD) measure is one of the National Committee for Quality Assurance (NCQA) HEDIS measures. It is used to evaluate whether those with schizophrenia and diabetes are having their cholesterol and blood glucose monitored. Patients taking antipsychotics are at increased risk for diabetes and cardiovascular disease. Lack of care can lead to a decline in health and outcomes.¹

Who is included in the SMD measure?

The percentage of patients with schizophrenia or schizoaffective disorder and diabetes who were 18–64 years old during the measurement year and meet at least one of the following criteria:

- At least one acute inpatient encounter with any diagnosis of schizophrenia or schizoaffective disorder
- At least two visits in an outpatient, intensive outpatient, partial hospitalization, emergency department (ED) or non-acute inpatient setting on different dates of service, with any diagnosis of schizophrenia or schizoaffective disorder
- Diagnostic events can also come from telehealth, online assessments, telephone and e-visits or virtual check-ins

How does a member become compliant?

One LDL-C test and an HbA1c test during the measurement year

Exclusions

Patients using hospice services

Measure best practices

- Use correct coding and submit claims in a timely manner.
- Refer patients with heart disease for annual lab draws; follow up to discuss results.
- Coordinate care with any treating behavioral health specialists.

SMD coding

Code type	Code	Description
CPT	80061, 83700, 83701, 83704, 83721	LDL-C tests
CPT II	3048F–3050F	LDL-C result or finding
CPT	83036, 83037	HbA1c tests
CPT II	3044F, 3045F, 3046F, 3051F, 3052F	HbA1c result or finding

¹National Committee for Quality Assurance. (2021, October 19). *Diabetes and Cardiovascular Disease Screening and Monitoring for People With Schizophrenia or Bipolar Disorder (SSD, SMD, SMC)*. Retrieved from NCQA.org: <https://www.ncqa.org/hedis/measures/diabetes-and-cardiovascular-disease-screening-and-monitoring-for-people-with-schizophrenia-or-bipolar-disorder/>

NCQA Copyright Notice and Disclaimer

The HEDIS measure specifications were developed by and are owned by NCQA. The HEDIS measure specifications are not clinical guidelines and do not establish a standard of medical care. NCQA makes no representations, warranties, or endorsement about the quality of any organization or physician that uses or reports performance measures and NCQA has no liability to anyone who relies on such measure specifications. NCQA holds a copyright in these materials and can rescind or alter these materials at any time. These materials may not be modified by anyone other than NCQA. Use of the Rules for Allowable Adjustments of HEDIS to make permitted adjustments of the materials does not constitute a modification. Any commercial use and/or internal or external reproduction, distribution and publication must be approved by NCQA and are subject to a license at the discretion of NCQA. Any use of the materials to identify records or calculate measure results, for example, requires a custom license and may necessitate certification pursuant to NCQA’s Measure Certification Program. Reprinted with permission by NCQA. ©2021 NCQA, all rights reserved.

Limited proprietary coding is contained in the measure specifications for convenience. NCQA disclaims all liability for use or accuracy of any third-party code values contained in the specifications.

The full text of this notice and disclaimer is available [here](http://apps.humana.com/marketing/documents.asp?file=4274309).
<http://apps.humana.com/marketing/documents.asp?file=4274309>